SCHEMBL805317

SCHEMBL805317

CCc1c(O)cc(C)oc1=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 2/20 0.47
ANTXR2 P58335 1/20 0.44
ESR1 P03372 3/20 0.44
ESR2 Q92731 3/20 0.44
MAOA P21397 1/20 0.43
GAA P10253 3/20 0.43
ALDH1A1 P00352 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
HPGD P15428 2/20 0.41
GLA P06280 2/20 0.41
KDM4E B2RXH2 2/20 0.41
HSD17B10 Q99714 2/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
MEN1 O00255 2/20 0.41
CYP3A4 P08684 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 3/20 0.41
TP53 P04637 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17866851 0.77 ESR1 (0.37) ESR1ESR2GAAALDH1A1HPGD
SCHEMBL16432837 0.76 ELANE (0.46) ELANEESR1ESR2ALDH1A1KDM4E
SCHEMBL7358719 0.74 RXRA (0.48) ESR1ESR2GAAALDH1A1HPGD
SCHEMBL29895902 0.74 RXRA (0.48) ESR1ESR2GAAALDH1A1HPGD
SCHEMBL29150895 0.74 ELANE (0.40) ELANEANTXR2MAOAGAAHPGD
SCHEMBL805313 0.74 MAPT (0.50) ELANEANTXR2MAOAGAAALDH1A1
SCHEMBL6175677 0.73 PGAM1 (0.47) MAOAGAAALDH1A1GLAKDM4E
SCHEMBL17867292 0.73 POLB (0.41) ELANEESR1ESR2GAAALDH1A1
SCHEMBL29895904 0.73 ESR1 (0.35) ELANEESR1ESR2GAAALDH1A1
SCHEMBL7963459 0.72 ALDH1A1 (0.45) ESR1ESR2GAAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170157111-A1 HIF INHIBITORS AND USE THEREOF THE GENERAL HOSPITAL CORPORATION (US) 2017-06-08 US disclosed
US-20120070369-A1 HIF INHIBITORS AND USE THEREOF THE GENERAL HOSPITAL CORPORATION (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120070369-A1 HIF INHIBITORS AND USE THEREOF HIF1AN, HIF1A, EGLN3 ELANE 1449/4885ANTXR2 1573/4885ESR1 1246/4885
US-20170157111-A1 HIF INHIBITORS AND USE THEREOF HIF1AN, HIF1A, EGLN3 ELANE 1449/4885ANTXR2 1573/4885ESR1 1246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.